Study of Serum Levels,Venous Irritation and Gastrointestinal Side-effects with Intravenous Erythromycin Lactobionate in Patients with Bronchopulmonary Infection
Restricted accessResearch articleFirst published online October, 1983
Study of Serum Levels,Venous Irritation and Gastrointestinal Side-effects with Intravenous Erythromycin Lactobionate in Patients with Bronchopulmonary Infection
1 Sixteen patients with bronchopulmonary infection received 500 mg erythromycin lactobionate by intravenous infusion every 8 h for 2 days. The duration of infusion was either 30 (8 patients) or 60 min (8 patients). An inline filterset (0.22 μm) was included in the intravenous administration set in 4 patients of each infusion group.
2 Serum erythromycin levels were obtained before and at various times for 8 h after the first and fourth doses and before and immediately after the other doses. The incidence and severity of venous irritation and gastrointestinal side-effects were assessed.
3 Mean (S.D.) peak erythromycin levels for the 30 min infusion were 26.31 (6.89) μg/ml (first dose) and 26.85 (6.11) μg/ml (fourth dose) and for the 60min infusions, 23.96 (7.91) μg/ml (first dose) and 23.65 (6.55) μg/ml (fourth dose).
4 Venous irritation was experienced by 12 patients, ranging from localized discomfort to thrombophlebitis, but the severity was significantly reduced by inline filtration (P < 0.005).
5 Gastrointestinal side-effects were reported by 8 patients and 1 patient withdrew because of severe abdominal pain and nausea. These symptoms were usually relieved by spasmolytic agents and possibly could be explained by high concentrations reaching the gut wall either by biliary excretion or direct transport from blood and stimulating smooth muscle motility.
Get full access to this article
View all access options for this article.
References
1.
Acocella, G., Mattiussi, R., Nicholis, F.S., Pallanza, R. & Tenconi, C.T. (1968). Biliary excretion of antibiotics in man. Gut, 9, 536-545.
2.
AmericanHOSPITAL FORMULATORY SERVICE (1981). Washington: American Society of Hospital Pharmacists.
3.
Austin, K.L., Mather, L.E., Philpot, C.R. & McDonald, P.J. (1980). Intersubject and dose-related variability after intravenous administration of erythromycin. Br. J. clin. Pharmac., 10,273-279.
4.
Bell, S.C., Hamman, J.W. & Grundy, W.E. (1969). Micromethod for assaying serum levels of erythromycin . Appl. Microbiol., 17, 88-92.
5.
Beumer, H.M., Dubourg, A.Y. & Soetens, A. (1978). Erythromycin succinate in the treatment of acute exacerbations of chronic bronchitis. Eur. J. clin. Pharmac. , 13, 25-27.
6.
Blenk, H., Blenk, B., Jahneke, G., Simm, K., Lucke, B.V. & Lafranier, D. (1980). Erythromycin infusions for treatment of infections in the ear, nose and throat region. J. int. med. Res., 8 (Suppl. 2), 41-46.
7.
Cade, J.F. & Pain, M.C.F. (1979). Intravenous erythromycin in adult chest infections in critically ill patients. Anaesth. Intens. Care, 7,143-147.
8.
Chelvan, P., Hamilton-Miller, J.M.T. & Brumfitt, W. (1979). Biliary excretion of erythromycin after parenteral administration. Br. J. clin. Pharmac., 8, 233-235.
9.
Chun, A.H.C. & Seitz, J.A. (1977). Pharmacokinetics and biological availability of erythromycin. Infection, 5 (Suppl. 1), 14-22.
10.
Clarke, C.W. & Marlin, G.E. (1982). Antibiotic treatment of pneumonia. Aust. N.Z. J. Med., 12, 85-89.
11.
Crawford, L.V. & Roane, J. (1969). Use of erythromycin ethyl succinate in allergic children. Ann. Allergy, 27, 18-22.
Eremin, O. & Marshall, V. (1977). Complications of intravenous therapy: Reduction by buffering of intravenous fluid preparation. Med. J. Aust. , 2, 528-531.
14.
Fraschini, F., Copponi, V., Dubini, F. & Scarpazza, G. (1978). Concentration of erythromycin and ampicillin in bronchial secretions in patients with chronic respiratory infections. Curr. med. Res. Opin., 5 (Suppl. 2), 23-27.
15.
Garrod, C.P., Lambert, H.P. & O'Grady, F. (1973). Antibiotic and Chemotherapy, pp. 167-175. Edinburgh and London: Churchill Livingstone .
16.
Hammond, J.B. & Griffith, R.S. (1961). Factors affecting the absorption and biliary excretion of erythromycin and two of its derivatives. Clin. Pharmac. Ther., 2, 308-312.
17.
Holland, B.R. & Quay, J.F. (1976). Intestinal secretion of erythromycin base. J. Pharmaceut. Sci., 65, 417-419.
18.
Huber, R.C. & Riffkin, C. (1975). In line final filters for removing particles from amphotericin B infusions. Am. J. hosp. Pharm., 32, 173-176.
19.
Keller, H. & Bircher, J. (1980). Miscellaneous antibiotics in Meyer's side effects of drugs, ed M. N. G. Dukes, 9th edn, pp. 452-573. Amsterdam: Excerpta Medica.
20.
Lacey, R.W. (1977). A new look at erythromycin. Postgrad. Med. J., 53, 195-200.
21.
Lee, C.C., Anderson, R.C. & Chen, K.K. (1956). Distribution and excretion of radioactivity in rats receiving N-methyl-14C erythromycin. J. Pharmac. exp. Ther., 117, 265-273.
22.
Lewis, V.J., Thacker, W.L., Shepard, C.C. & McDade, J.E. (1978). In vivo susceptibility of the Legionnaires disease bacterium to ten antimicrobial agents. Antimicrob. Agents Chemother., 13, 419-422.
23.
Lhoste, F., Lemaire, F., Tillement, J.P., Duval, J. & Rapin, M. (1980). Erythromycin lactobionate as a first-choice parenteral antibiotic in severe infective exacerbations of chronic bronchitis. Int. Congress Chemother., 11, 1018-1019.
24.
Maddox, R.R., Rush, D.R., Rapp, R.P., Foster, T.S., Mazella, V. & McKean, H.E. (1977). Double-blind study to investigate methods to prevent cephalothin-induced phlebitis. Am. J. hosp. Pharm., 34, 29-34.
25.
Marlin, G.E., Davis, P.R., Rutland, J. & Berend, N. (1980). Plasma and sputum erythromycin concentrations in chronic bronchitis. Thorax, 35, 441-445.
26.
Masuda, J.Y. & Beckerman, J.H. (1973). Particulate matter in commercial antibiotic injectable products. Am. J. hosp. Pharmac., 30, 72-76.
27.
Mather, L.E., Austin, K.L., Philpot, C.R. & McDonald, P.J. (1981). Absorption and bioavailability of oral erythromycin. Br. J. clin. Pharmac., 12, 131-140.
28.
May, J.R. (1972). The chemotherapy of chronic bronchitis and allied disorders. London: The English Universities Press Ltd.
29.
Meade, R.H. (1979). Antimicrobial spectrum, pharmacology and the therapeutic use of erythromycin and its derivatives. Am. J. hosp. Pharm. , 36,1185-1189.
30.
Neaverson, M.A. (1976). Intravenous administration of erythromycin: serum, sputum and urine levels. Curr. med. Res. Opin., 4, 359-364.
31.
Parsons, R.L., David, J.A., Paddock, G.M. & Stamp, S.M. (1978). Plasma concentration/time curve of erythromycin after a 12 h intravenous infusion of erythromycin lactobionate in man. Postgrad. Med. J., 54, 68-71.
32.
Parsons, R.L., David, J.A., Raymond, K. & Stamp, S.M. (1980). Pharmacokinetics of intravenous erythromycin lactobionate . J. int. med. Res., 8 (Suppl. 2), 15-23.
33.
Rusho, W.J. & Barr, J.M. (1979). Effect of filtration on complications of post-operative intravenous therapy. Am. J. hosp. Pharm., 36,1355-1356.
34.
Ryan, P., Rapp, R.P., Deluca, P.P., Griffin, W.O., Clark, J.D. & Cloys, D. (1973). In-line filtration. A method of minimizing contamination in intravenous therapy. Am. J. hosp. Pharm., 36,1355-1356.
35.
San Filippo, J.A. (1976). Infantile hypertrophic pyloric stenosis related to ingestion of erythromycin estolate. A report of five cases. J. paediat . Surg., 11, 177-180.
36.
Sietzen, W. (1982). Pharmacokinetics of 1000 mg erythromycin lactobionate i.v. in patients with respiratory tract infections. Infection , 10 (Suppl. 2), S99-S101.
37.
Simmen, H.P. & Luthy, R. (1982). Erythromycin (2 x 1 g) as a regimen for community-acquired pneumonia. Infection, 10 (Suppl. 2), S84-S85.
38.
Simon, C. & Clasen, I. (1978). Sputum levels of erythromycin after single and repeated oral administration in adult patients with bronchitis. Curr. med. Res. Opin., 5 (Suppl. 2), 19-20.
39.
Takimura, Y. & Lopez, B.M. (1955). Excretion of erythromycin through the biliary tract. AntibioticsMed., 1, 561-566.
Weinstein, L. (1980). The 'new' pneumonias. The doctor's dilemma. Ann. intern. Med., 92, 559-561.
42.
Willey, R.F., Gould, J.C. & Grant, I.W.B. (1978). A comparison of ampicillin, erythromycin and erythromycin with sulphametopyrazine in the treatment of infective exacerbations of chronic bronchitis. Br. J. Dis. Chest, 72, 13-20.
